Samsung Submits MAA for Remicade Biosimilar For Crohn’s Disease, Ulcerative Colitis to EMA
Crohn's Disease, News, Ulcerative colitis
Samsung Bioepis Co. Ltd. recently submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) regarding a biosimilar treatment for several conditions, including Crohn’s disease and ulcerative colitis. The Remicade (Infliximab) ... Read more